Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: committee papers
Table of Contents
01. NICE's response to comments on the Appraisal Consultation Document (ACD)
02. Consultee comments on the ACD - AbbVie
03. Consultee comments on the ACD - British Society of Gastroenterology
04. Consultee comments on the ACD - Crohns & Colitis UK
05. Consultee comments on the ACD - Department of Health
06. Consultee comments on the ACD - Merck Sharpe and Dohme
07. Consultee comments on the executable model - Merck & Sharpe and Dohme
08. Consultee comments on the ACD - Royal College of Nursing
09. Consultee comments on the ACD - Royal College of Physicians
10. Consultee comments on the ACD - Takeda
11. Comments on the ACD - Thanet CCG and South Kent Coast CCG
12. Comments on the ACD - United Kingdom Clinical Pharmacy Association
13. Patient expert comments on the ACD - Cleaver
14. Patient expert comments on the ACD - Singh
15. Public comments on the ACD received via the NICE website
Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: committee papers
13 March 2015 (2.95 Mb 40 sec) |
This page was last updated: 11 March 2015